Bottom line
DLRHX vs VOO: the short answer
DLRHX (Nomura Healthcare Fund) and VOO (Vanguard 500 Index Fund) are both mutual funds.
But VOO is far broader, holding 520 positions to 108 for DLRHX, so beyond the top names it adds exposure DLRHX doesn't have.
VOO is cheaper at 0.03% vs 1.46% — a difference of $143 a year per $10,000 invested.
Over five years, VOO returned +14.4% a year vs +7.2% for DLRHX.
Updated Nov 19, 2026
DLRHX vs VOO side by side
| DLRHX | VOO | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Voya | Vanguard |
| Category | Health Care Sector | S&P 500 Index |
| Expense ratio | 1.46% | 0.03% |
| Annual cost per $10k | $146 | $3 |
| 10-yr cost on $10k (prospectus) | $1,797 | $39 |
| Max front load | 0% | None |
| 12b-1 fee | 0.5% | 0% |
| 1-yr return | +21.8% | +17.8% |
| 5-yr return (annualized) | +7.2% | +14.4% |
| 10-yr return (annualized) | +9.9% | +14.8% |
| Best quarter | — | +20.5% |
| Worst quarter | — | −19.6% |
| Net assets (fund) | $750.2M | $1.7T |
| Number of holdings | 108 | 520 |
| Portfolio turnover | 4% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
2 of DLRHX's top 25 holdings also appear in VOO's top 25.
| Holding | DLRHX | VOO |
|---|---|---|
| Abbvie Inc | 4.19% | 0.69% |
| Eli Lilly & Company | 4.16% | 1.47% |
Source: SEC Form N-PORT
DLRHX top 10
- Ucb Sa — 5.19%
- Abbvie Inc — 4.19%
- Eli Lilly & Company — 4.16%
- Regeneron Pharmaceuticals Inc — 3.91%
- Unitedhealth Group Inc — 3.88%
- Pfizer Inc — 3.84%
- Merck & Company Inc — 3.68%
- Gilead Sciences Inc — 3.54%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
VOO top 10
- NVIDIA Corp — 7.51%
- Apple Inc — 6.59%
- Microsoft Corp — 4.30%
- Amazon.com Inc — 3.62%
- Alphabet Inc — 3.25%
- Broadcom Inc — 2.77%
- Alphabet Inc — 2.59%
- Micron Technology Inc — 2.02%
- Meta Platforms Inc — 1.92%
- Tesla Inc — 1.84%
FAQ
What is the difference between DLRHX and VOO?
Which is cheaper, DLRHX or VOO?
Should I own both DLRHX and VOO?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.